<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Dear Select Committee Members</title></head><body><div><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by The Haemophilia Society (BTO0009)</span></p><p style="font-size:11pt; line-height:115%; margin:5pt 0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">Thank you for the invitation to respond to your </span><span style="font-family:'Times New Roman'; font-size:11pt">inquiry on blood, tissue and organ screening. We understand that this follows on from an evidence session held on the subject of Variant Creutzfeldt-Jakob Disease (</span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">).</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">The Haemophilia Society is the only UK wide independent organisation representing patients with inherited bleeding disorders. In response to the Select Committee’s call for written evidence, in consultation with our Clinical Advisory Group, led by Professor Michael </span><span style="font-family:'Times New Roman'; font-size:11pt">Makris</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">Professor of </span><span style="font-family:'Times New Roman'; font-size:11pt">Haemostasis</span><span style="font-family:'Times New Roman'; font-size:11pt"> &amp; Thrombosis at the University of Sheffield, </span><span style="font-family:'Times New Roman'; font-size:11pt">we offer the following:</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Summary of evidence</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">People with bleeding disorders are acutely aware of the importance of ensuring the purity of blood products following previous product contamination with lethal viruses</span></li></ul><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There should be a clear evidence base for who can donate blood, tissues and organs, including a review of evidence from other countries</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The UK should move to exclusively using  fibrinogen concentrate which does not have the </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> risk</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 28.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The</span><span style="font-family:'Times New Roman'; font-size:11pt"> costs and benefits of developing and implementing an effective test for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> should be considered</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">1</span><span style="font-family:'Times New Roman'; font-size:11pt"> Following the contamination of whole blood and blood products in the 1970s and 1980s with the lethal viruses HIV and hepatitis C, the population of people with </span><span style="font-family:'Times New Roman'; font-size:11pt">Haemophilia</span><span style="font-family:'Times New Roman'; font-size:11pt"> and other bleeding disorders would look to the government and health service to take every reasonable precaution to </span><span style="font-family:'Times New Roman'; font-size:11pt">minimise</span><span style="font-family:'Times New Roman'; font-size:11pt"> risk. </span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">This would include documenting a clear evidence base for decision making on who can donate blood, tissues, and organs, and publishing explanations for its decision making, to include a review of evidence and practice from other countries. </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2</span><span style="font-family:'Times New Roman'; font-size:11pt"> As a result of exposure to clotting factors made from UK human plasma 3,058 persons with inherited bleeding disorders (most of who suffer from haemophilia) are now considered to be at risk for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> for public health purposes. 801 of these individuals have been treated with concentrates made from the plasma of persons who have subsequently died from </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3</span><span style="font-family:'Times New Roman'; font-size:11pt"> Since 2004 all patients with haemophilia have been treated with recombinant concentrates which do not use human plasma in the manufacturing process and do not have a risk of transfusion transmitted infections such as </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt">, HIV or hepatitis C.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4</span><span style="font-family:'Times New Roman'; font-size:11pt"> Cryoprecipitate is a blood product made from human plasma. Once a donor donates a unit of blood, it is made into red cells, fresh frozen plasma and cryoprecipitate. None of these products undergo any viral inactivation in the UK. Cryoprecipitate is rich in a clotting factor called fibrinogen.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5</span><span style="font-family:'Times New Roman'; font-size:11pt"> When a patient requires fibrinogen replacement there are two ways of doing this:</span></p><ul type="disc" style="margin:0pt; padding-left:0pt"><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Administer cryoprecipitate which is given as multiples of 10 donor units at a time. As already indicated this is not virally inactivated, and has the risk of </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> since 1 in 2,000 units will have been donated by an individual with </span><span style="font-family:'Times New Roman'; font-size:11pt">prions</span><span style="font-family:'Times New Roman'; font-size:11pt"> in their lymphoid tissue.</span></li><li style="font-family:Symbol; font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 46.06pt; padding-left:7.94pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Administer fibrinogen concentrate. This is prepared from plasma donations obtained from countries without the </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> problem (</span><span style="font-family:'Times New Roman'; font-size:11pt">ie</span><span style="font-family:'Times New Roman'; font-size:11pt"> not UK or France) and furthermore it is virally inactivated to reduce the risk of transmitting infections.</span></li></ul><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">6</span><span style="font-family:'Times New Roman'; font-size:11pt"> Fibrinogen replacement is required by patients with bleeding due to inherited as well as acquired deficiencies of fibrinogen. Acquired deficiencies of fibrinogen are seen in patients after major injuries such as road traffic accidents as well as when major bleeding occurs at the time of delivery of pregnancy. In the UK cryoprecipitate is the main product used in these circumstances and, since it is given as multiples of 10 units at a time, it is not unusual for a patient to be exposed to more than 30 donors in one day.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">7</span><span style="font-family:'Times New Roman'; font-size:11pt"> Because of the risk of transfusion transmitted infection, all the transfusion centres in Europe except the UK have stopped making and providing cryoprecipitate. All European countries except the UK are now using exclusively fibrinogen concentrate which does not have the </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> risk.  It is ironic that the UK, the only country in Europe with a possible </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> risk, is the only one continuing to use cryoprecipitate, rather than use the safer alternative.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">8</span><span style="font-family:'Times New Roman'; font-size:11pt"> The British Committee for Standards in Haematology has recommended that the UK should discontinue using cryoprecipitate and move to using fibrinogen concentrate which is considered as a safer alternative. The Haemophilia Society strongly supports this recommendation.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">9</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">Additionally we ask the committee to consider that</span><span style="font-family:'Times New Roman'; font-size:11pt"> the UK reviews</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">the</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">current state of testing for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> and look at the costs and benefits of developing and implementing an effective test for </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD</span><span style="font-family:'Times New Roman'; font-size:11pt"> for blood donations and for individuals, taking into account the ethical and psychological impact of testing.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>